These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ; J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445 [TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L Lung; 2005; 183(4):265-72. PubMed ID: 16211462 [TBL] [Abstract][Full Text] [Related]
19. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. Lapointe R; Létourneau R; Steward W; Hawkins RE; Batist G; Vincent M; Whittom R; Eatock M; Jolivet J; Moore M Ann Oncol; 2005 Feb; 16(2):289-93. PubMed ID: 15668286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]